Prelude Therapeutics Inc (PRLD) stock

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 8/3075% above fair value

$3.52−0.26 (-6.88%)

Close on Nov 12, 2026Market cap $280.91MP/E –Yield –

Prelude Therapeutics statistics

72 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Q3 FY2026, expected soon
Last ex-dividend date: No dividends
Fundamentals through: Jun 30, 2026
Share price as of: Nov 12, 2026

Valuation ratiosIndustry

Market Cap: $280.91M; $280.48M
Enterprise Value: $129.15M; $148.62M
PS Ratio: 12.53; 3.60
PB Ratio: 2.10; 2.05
P/TBV Ratio: 2.10; 2.29

Enterprise valuationIndustry

EV / Sales: 5.76; 2.60

Share statisticsIndustry

Shares Outstanding: 80M; 58M
Shares Change (YoY): 10.9%; 10.9%
Float: 47M; 49M
Shares Held by Insiders: 40.5%; 12.1%
Shares Held by Institutions: 62.2%; 56.4%

Short sellingIndustry

Short Interest: 4M; –
Short Interest Change: -18.0%; -0.76%
Short % of Float: 8.80%; 9.06%
Short % of Shares Outstanding: 5.23%; 6.30%
Days to Cover: 9.14; 5.13

Stock price statisticsIndustry

52-Week High: $6.83; –
52-Week Low: $1.29; –
20-Day Moving Average: $3.72; –
50-Day Moving Average: $4.04; –
200-Day Moving Average: $4.09; –
Average True Range (14): $0.33; –
Price Change (1 Week): -0.98%; 1.51%
Price Change (1 Month): 8.98%; -2.37%
Price Change (3 Months): -36.6%; -21.1%
Price Change (6 Months): -21.3%; -22.8%
Price Change (YTD): 21.4%; -22.6%
Price Change (1 Year): 160.7%; -21.0%
Price Change (3 Years): 16.9%; -24.8%
Price Change (5 Years): -78.3%; -76.9%
Average Volume (10 Days): 248,189; –
Average Volume (20 Days): 366,296; –
Average Volume (90 Days): 449,261; –
Relative Volume: 0.51; 0.80
Relative Strength Index (14): 41.9; 44.7
Volatility (1 Year): 109.1%; 80.2%
Beta (5 Years): 1.23; 1.07

MarginsIndustry

Operating Margin: -300.6%; -38.5%
Profit Margin: -269.7%; -31.7%
EBITDA Margin: -293.5%; -27.7%
FCF Margin: -148.3%; -8.85%

Returns on capitalIndustry

Return on Equity (ROE): -57.7%; -51.3%
Return on Assets (ROA): -39.8%; -40.7%
Return on Capital Employed (ROCE): -44.5%; -38.1%

Financial positionIndustry

Current Ratio: 4.07; 3.31
Quick Ratio: 3.99; 2.41

GrowthIndustry

Revenue Growth (YoY): 220.3%; 7.26%

EfficiencyIndustry

Asset Turnover: 0.15; 0.40
Revenue Per Employee: $283.85K; $429.38K
Profits Per Employee: -$765.67K; -$683.67K
Employee Count: 79; 75
WACC: 11.0%; 10.0%

Income statement (TTM)Industry

Revenue: $22.42M; $66.69M
Operating Income: -$67.40M; -$20.99M
Net Income: -$60.49M; -$21.61M
EBITDA: -$65.81M; -$16.85M
EPS (Diluted): -$0.74; -$0.75

Balance sheetIndustry

Cash & Short-Term Investments: $151.76M; $67.18M
Net Cash (Debt): $151.76M; $16.98M
Net Cash Per Share: $1.90; $0.72
Equity (Book Value): $133.73M; $52.68M
Book Value Per Share: $1.68; $1.50
Tangible Book Value: $133.73M; $26.74M
Working Capital: $116.86M; $78.52M

Cash flow (TTM)Industry

Operating Cash Flow: -$33.26M; -$12.27M
Capital Expenditures: $0; -$944.00K
Free Cash Flow: -$33.26M; -$18.20M
FCF Per Share: -$0.42; -$0.42

Dividends and yieldsIndustry

Earnings Yield: -21.5%; -21.0%
FCF Yield: -11.8%; -9.44%

Scores and fair valueIndustry

Altman Z-Score: -2.52; 0.26
Piotroski F-Score: 3; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

Period	PRLD	S&P 500	Difference	PRLD per year	S&P 500 per year
1 month	-5.9%	-2.7%	−3.2 pts
3 months	-38.6%	-1.7%	−36.8 pts
Year to date	+21.4%	+11.9%	+9.5 pts
1 year	+139.5%	+12.0%	+127.5 pts
3 years	+16.9%	+78.2%	−61.2 pts	+5.4%	+21.2%
5 years	-78.3%	+73.2%	−151.5 pts	-26.3%	+11.6%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

4M PRLD shares were sold short on Oct 30, 2026, down 18.0% from the previous report, or 8.80% of the shares available to trade. At recent volumes it would take 9.1 days to buy them back. Over the last 20 sessions, 48.2% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	4,177,566	-18.0%	456,823	9.1
Oct 15, 2026	5,097,463	+11.4%	444,224	11.5
Sep 30, 2026	4,575,044	+26.2%	578,215	7.9
Sep 15, 2026	3,626,569	+0.9%	402,893	9.0
Aug 31, 2026	3,593,582	-5.8%	643,302	5.6
Aug 14, 2026	3,816,602	+4.0%	391,381	9.8
Jul 31, 2026	3,669,933	+11.7%	394,222	9.3
Jul 15, 2026	3,286,206	+16.4%	344,545	9.5
Jun 30, 2026	2,822,240	+57.4%	812,143	3.5
Jun 15, 2026	1,792,865	+5.8%	285,513	6.3
May 29, 2026	1,693,810	-8.5%	315,004	5.4
May 15, 2026	1,851,622	+19.1%	522,874	3.5

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Prelude Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRLD.

Compare: PRLD vs TNGX · PRLD vs JANX · PRLD vs CBIO · PRLD vs PYXS · PRLD vs ZNTL

Revenue growth220.3% · median 16.4%

Operating margin-300.6% · median -907.9%

Net margin-269.7% · median -578.2%

Company	Revenue	Growth
JANX	$23.29M	+132.9%
PRLD	$22.42M	+220.3%
CBIO	$15.00M	–
TNGX	$0	-100.0%
PYXS	–	–
ZNTL	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 79
Held by institutions: 62.2%
Auditor: Ernst & Young LLP
SEC CIK: 1678660

Advertisement
300 × 250

See a number that looks wrong?